Adam Henry

Adam is a Senior Diagnostics Corporate Development Executive Adam brings over 27 years of biotechnology industry experience, currently serving as the Head of Strategy, Marketing, and Business Development at Truvian Health since June 2024 and as a board director for OncoGenesis since 2022. Prior to Truvian, Adam was Senior Vice President of Corporate Development at Proof Diagnostics, co leading the effort to successfully sell the company to Ginkgo Bioworks in August 2023. Adam’s career functional responsibilities have ranged in scope from corporate strategy, business development (M&A) and marketing, specifically within the diagnostics arena over the past 15 years, to product development and operations as a product design engineer earlier in his career at Invitrogen (now part of ThermoFisher Scientific) and Dura Pharmaceuticals (acquired by Elan Pharmaceuticals). Prior to joining Proof Dx in May 2022, Adam served as Head of Strategy and Business Development at Roche subsidiary GenMark Dx. Before that, he held senior management roles at Siemens Healthineers, Hologic, and Gen Probe (acquired by Hologic) in strategy, business development and upstream marketing. During his tenure, Gen Probe launched several highly innovative products including the PANTHER® molecular diagnostic system and the APTIMA® HPV screening assay, and the company’s value doubled, creating nearly $2 billion in value for shareholders, culminating in a successful sale of the business to Hologic in 2012 for $3.7 billion. In total, Adam has facilitated nearly $6 billion in molecular diagnostics transactions since 2009. Adam holds an MBA from the UCLA Anderson School of Management and a BS degree in Mechanical Engineering from the University of Nevada.